MAVYRET™ (glecaprevir + pibrentasvir)


































  • Mavyret is approved for treatment in adults and pediatric patients 12 years and older or weighing at least 99 lbs (45 kg)
Treatment-naïve patients - HCV Genotype 1, 2, 3, 4, 5, and 6
Liver disease Treatment
No cirrhosis Three Mavyret tablets once daily with food for 8 weeks
Child-Pugh A Three Mavyret tablets once daily with food for 12 weeks

  • PRS = Prior treatment with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir
  • In trials, prior NS5A inhibitor treatment included ledipasvir and daclatasvir
  • In trials, prior NS3/4A PI treatment included simeprevir, boceprevir, or telaprevir
  • Mavyret is approved for treatment in adults and pediatric patients 12 years and older or weighing at least 99 lbs (45 kg)
Treatment-experienced patients
HCV GN Previous treatment No cirrhosis Child-Pugh A
1 An NS5A inhibitor without prior treatment with an NS3/4A protease inhibitor 16 weeks 16 weeks
1 An NS3/4A protease inhibitor without prior treatment with an NS5A inhibitor 12 weeks 12 weeks
1, 2, 4, 5, 6 PRS 8 weeks 12 weeks
3 PRS 16 weeks 16 weeks

  • PRS = Prior treatment with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir
  • In trials, prior NS5A inhibitor treatment included ledipasvir and daclatasvir
  • In trials, prior NS3/4A PI treatment included simeprevir, boceprevir, or telaprevir
  • Mavyret is approved for treatment in adults and pediatric patients 12 years and older or weighing at least 99 lbs (45 kg)
Liver or kidney transplant recipients
HCV GN Previous treatment Duration
1, 2, 3, 4, 5, 6 None 12 weeks
1 NS5A inhibitor-experienced without prior treatment with an NS3/4A protease inhibitor 16 weeks
3 PRS treatment-experienced 16 weeks